Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.

Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.

Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniatte M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Masliah E, Lashuel HA.

J Neurosci. 2010 Mar 3;30(9):3184-98. doi: 10.1523/JNEUROSCI.5922-09.2010.

2.
3.

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. Review.

PMID:
19711118
4.

Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease.

Oueslati A, Paleologou KE, Schneider BL, Aebischer P, Lashuel HA.

J Neurosci. 2012 Feb 1;32(5):1536-44. doi: 10.1523/JNEUROSCI.3784-11.2012.

5.

Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.

Tsika E, Moysidou M, Guo J, Cushman M, Gannon P, Sandaltzopoulos R, Giasson BI, Krainc D, Ischiropoulos H, Mazzulli JR.

J Neurosci. 2010 Mar 3;30(9):3409-18. doi: 10.1523/JNEUROSCI.4977-09.2010.

6.

Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Waxman EA, Giasson BI.

J Neuropathol Exp Neurol. 2008 May;67(5):402-16. doi: 10.1097/NEN.0b013e31816fc995.

7.

Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.

Wu J, Lou H, Alerte TN, Stachowski EK, Chen J, Singleton AB, Hamilton RL, Perez RG.

Neuroscience. 2012 Apr 5;207:288-97. doi: 10.1016/j.neuroscience.2012.01.028. Epub 2012 Jan 25.

8.

Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, Askay D, Cartier A, Spencer B, Patrick C, Desplats P, Ellisman MH, Masliah E.

PLoS One. 2010 Nov 16;5(11):e14020. doi: 10.1371/journal.pone.0014020.

9.

Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.

Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WD, Forrest SL, Parkkinen L, Gai WP, Hattori N, Takanashi M, Lee SJ, Mann DM, Imai Y, Halliday GM, Li JY, El-Agnaf OM.

Neurobiol Dis. 2015 Jul;79:81-99. doi: 10.1016/j.nbd.2015.04.009. Epub 2015 Apr 30.

PMID:
25937088
10.

ɑ-Synuclein strains and the variable pathologies of synucleinopathies.

Peelaerts W, Baekelandt V.

J Neurochem. 2016 Oct;139 Suppl 1:256-274. doi: 10.1111/jnc.13595. Epub 2016 Mar 30. Review.

11.

Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization.

Samuel F, Flavin WP, Iqbal S, Pacelli C, Sri Renganathan SD, Trudeau LE, Campbell EM, Fraser PE, Tandon A.

J Biol Chem. 2016 Feb 26;291(9):4374-85. doi: 10.1074/jbc.M115.705095. Epub 2015 Dec 30.

12.

Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.

Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E.

Exp Neurol. 2010 Feb;221(2):267-74. doi: 10.1016/j.expneurol.2009.11.015. Epub 2009 Nov 26.

13.

The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.

Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N.

Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):763-8. doi: 10.1073/pnas.0711053105. Epub 2008 Jan 4.

14.

SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.

Henderson-Smith A, Chow D, Meechoovet B, Aziz M, Jacobson SA, Shill HA, Sabbagh MN, Caviness JN, Adler CH, Driver-Dunckley ED, Beach TG, Yin H, Dunckley T.

PLoS One. 2013 Oct 30;8(10):e77711. doi: 10.1371/journal.pone.0077711. eCollection 2013.

15.

Synucleinopathies: clinical and pathological implications.

Galvin JE, Lee VM, Trojanowski JQ.

Arch Neurol. 2001 Feb;58(2):186-90. Review.

PMID:
11176955
16.

Phosphorylation of synucleins by members of the Polo-like kinase family.

Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, Lashuel HA.

J Biol Chem. 2010 Jan 22;285(4):2807-22. doi: 10.1074/jbc.M109.081950. Epub 2009 Nov 4.

17.

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.

Zhou W, Milder JB, Freed CR.

J Biol Chem. 2008 Apr 11;283(15):9863-70. doi: 10.1074/jbc.M710232200. Epub 2008 Jan 30.

18.

Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.

Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, Spencer B, Rockenstein E, Trejo M, Platoshyn O, Yuan JX, Masliah E.

PLoS One. 2008 Sep 4;3(9):e3135. doi: 10.1371/journal.pone.0003135.

19.

Formation and development of Lewy pathology: a critical update.

Jellinger KA.

J Neurol. 2009 Aug;256 Suppl 3:270-9. doi: 10.1007/s00415-009-5243-y. Review.

PMID:
19711116
20.

α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.

Spencer B, Kim C, Gonzalez T, Bisquertt A, Patrick C, Rockenstein E, Adame A, Lee SJ, Desplats P, Masliah E.

Hum Mol Genet. 2016 Mar 15;25(6):1100-15. doi: 10.1093/hmg/ddv633. Epub 2016 Jan 5.

Supplemental Content

Support Center